Avoro Capital Advisors 13F: New $26M Stake in AVTX

Avoro Capital Advisors has taken a new position in Avalo Therapeutics, Inc. (NasdaqCM: AVTX), according to its latest filing with the SEC. The firm bought 1.41 million shares of the biotechnology company, valued at approximately $19.29 million. This move, reported on May 15, 2026, reflects Avoro's confidence in Avalo's potential.

What Changed in Avoro Capital Advisors' Avalo Therapeutics Position

Avoro Capital Advisors initiated its investment in Avalo Therapeutics by acquiring 1.41 million shares. This is a brand new position for the firm, which did not hold any shares of Avalo before this purchase. The shares are valued at about $19.29 million, marking a significant entry into the stock.

Other Institutional Activity in Avalo Therapeutics

Other institutional investors have also been active in Avalo Therapeutics. FMR LLC expanded its stake by 2.66 million shares, ending with 2.88 million shares worth around $42.99 million. T. Rowe Price Investment Management entered with 2.16 million shares valued at $32.29 million. Caligan Partners LP increased its holdings by 753,490 shares to 1.64 million shares, valued at $24.41 million. BVF Inc/IL added 277,588 shares, bringing its total to 1.63 million shares worth approximately $24.38 million.

Avalo Therapeutics, Inc. Stock Up 11.5%

Shares of Avalo Therapeutics (NasdaqCM: AVTX) are currently trading near $13.68. The company, which has a market cap of $775.87 million, is not yet profitable, reflected in its negative forward P/E ratio of -5.27. Avalo's stock has seen a 52-week low of $4.46 and a high of $24.27, with a 50-day moving average of $15.55 and a 200-day moving average of $15.45. The firm maintains a strong liquidity position with a current ratio of 7.66 and a quick ratio of 7.07.

Insider Buying and Selling at Avalo Therapeutics, Inc.

Recent insider transactions at Avalo Therapeutics include sales by several executives on June 10, 2026. Chief Strategy Officer Jennifer Riley, Chief Financial Officer Christopher Ryan Sullivan, Chief Legal Officer Paul Varki, and Chief Medical Officer Mittie Doyle sold small amounts of stock at $13.10 per share. Conversely, on June 2, 2026, Michael Thomas Heffernan and Aaron Kantoff acquired 29,500 and 20,100 shares, respectively, at zero cost.

Analysts Set New Price Targets

Analysts remain optimistic about Avalo Therapeutics. On June 12, 2026, B of A Securities initiated coverage with a buy rating and a $35 price target. On May 14, 2026, several firms, including Citizens and Wedbush, maintained buy ratings with targets ranging from $34 to $55. Analysts have a strong buy consensus, with a target mean price of $46.18 based on 11 opinions.

About Avalo Therapeutics

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company based in Wayne, Pennsylvania. The company focuses on developing treatments for immune-mediated inflammatory diseases, particularly using IL-1β-based therapies. Its lead product, AVTX-009, is a monoclonal antibody currently in phase 2 clinical trials. Avalo was founded in 2011 and is led by CEO Dr. Garry A. Neil.

Bottom Line

Avoro Capital Advisors' new position in Avalo Therapeutics is a notable development, reflecting potential confidence in the company's future prospects. Avalo, trading on the Nasdaq with the ticker AVTX, remains a key player in the biotechnology sector. Institutional and insider activity, along with analyst ratings, provide valuable insights, though it's important to remember that 13F filings are backward-looking and may not reflect current holdings.